These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29736470)

  • 1. Heart rate modulation in stable coronary artery disease without clinical heart failure: What we have already learned from SIGNIFY?
    Perna GP; Vagnarelli F; Volterrani M; Battistoni I; Rapezzi C
    Contemp Clin Trials Commun; 2016 Dec; 4():58-63. PubMed ID: 29736470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study?].
    Perna GP; Battistoni I; Angelini L
    G Ital Cardiol (Rome); 2015 Mar; 16(3):155-60. PubMed ID: 25837459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S; Timmis AD
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    Eur Heart J; 2015 Dec; 36(46):3291-6. PubMed ID: 26385957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Ivabradine in Managing Symptomatic Patients with Chronic Coronary Syndromes: A Clinically Oriented Approach.
    Gowdak LHW
    Cardiol Ther; 2022 Mar; 11(1):163-174. PubMed ID: 34860357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the SIGNIFY trial.
    Grassi G
    Expert Opin Pharmacother; 2015; 16(12):1861-4. PubMed ID: 26153241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine for Treatment of Coronary Artery Disease: From Last Chance Resort to Mainstem of a Reasoned Therapy.
    Lupi A; Rognoni A; Cavallino C; Secco GG; Rosso R; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):4-9. PubMed ID: 25544120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
    Borer JS; Deedwania PC; Kim JB; Böhm M
    Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
    Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
    Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A; Tardif JC
    Adv Cardiol; 2006; 43():65-78. PubMed ID: 16936473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering.
    Niccoli G; Borovac JA; Vetrugno V; Camici PG; Crea F
    Int J Cardiol; 2017 Jun; 236():107-112. PubMed ID: 28256323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Ivabradine in Combination with Beta-Blockers Versus Uptitration of Beta-Blockers in Patients with Stable Angina (CONTROL-2 Study).
    Glezer M; Vasyuk Y; Karpov Y
    Adv Ther; 2018 Mar; 35(3):341-352. PubMed ID: 29508153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
    Weeda ER; Nguyen E; White CM
    Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivabradine: the hope for a good treatment of ischemic heart disease.
    Riccioni G
    Curr Med Chem; 2013; 20(14):1817-23. PubMed ID: 23394554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
    Jedlickova L; Merkovska L; Jackova L; Janicko M; Fedacko J; Novakova B; Chmelarova A; Majernik J; Pella D
    Adv Ther; 2015 Oct; 32(10):962-70. PubMed ID: 26525390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.